Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2 Year Prospective Multicentre Randomised Controlled Trial Comparing Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis

Next Previous
Trial Profile

A 2 Year Prospective Multicentre Randomised Controlled Trial Comparing Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leflunomide (Primary) ; Methotrexate (Primary) ; Prednisone (Primary) ; Sulfasalazine (Primary) ; Glucocorticoids; Leflunomide
  • Indications Rheumatoid arthritis
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms CareRA

Most Recent Events

  • 05 Jun 2021 Results (n=379) determining the optimal statistical model and clinical factors to predict the time to a treatment adaptation in early RA patients, presented at the 22nd Annual Congress of the European League Against Rheumatism
  • 06 Jun 2020 Results evaluating novel RA autoantibody biomarkers that predict therapy response to csDMARDs before the initiation of treatment presented at the 21st Annual Congress of the European League Against Rheumatism
  • 06 Jun 2020 5 year outcomes of the Carera trial; results presented at the 21st Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top